Navigation Links
CutisPharma Expands Product Line with New Oral Suspension Prescription Compounding Kits

WOBURN, Mass., Jan. 19, 2012 /PRNewswire/ -- CutisPharma, Inc. announced the introduction of FIRST® - Omeprazole and FIRST® - Lansoprazole Unit-of-Use oral suspension compounding kits. These new kits will help pharmacists dispense these compounded prescriptions containing widely used proton pump inhibitors (PPIs). Traditionally, compounded omeprazole and lansoprazole oral suspensions can take up to several hours to prepare and are quite unpleasant to the taste.  With FIRST® - Omeprazole and FIRST® - Lansoprazole, pharmacists need only add the liquid suspension to the powder, shake, and then within minutes can dispense to the patient with improved flavoring.

"We invested a lot of time to develop these new suspension kits.  The results are a pleasant tasting strawberry flavored medication with adequate stability once compounded," said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc.  "These products offer another advantage for hospital use; since the suspensions are made using powders, and not pellets, our new compounded suspensions will flow more easily through nasogastric (NG) tubes, with minimal clogging compared to current practice. Also, our three different sizes of packaging, 3oz, 5oz, and 10oz, provide considerable prescribing flexibility."

FIRST® products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction.  Using FIRST® - Omeprazole and FIRST® - Lansoprazole kits, the pharmacist can compound a prescription faster than those prepared in the conventional way.  A single NDC number assigned for the entire Kit facilitates the third party reimbursement process, and reduces audit-related adjustments.

CutisPharma now has twenty proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, six Magic Mouthwash kits, three omeprazole suspension kits, and three lansoprazole suspension kits.  Several more compounding kits are in the planning stages. The use of FIRST® Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>.

The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through "compounding," a means by which a pharmacist prepares a customized medication according to a doctor's prescription to meet an individual patient's medical need.  About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually. 

About CutisPharma

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST®  Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Three U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at


SOURCE CutisPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line
2. Centrix Pharmaceutical, Inc. Announces Agreement With CutisPharma, Inc. to Promote FIRST® - Progesterone VGS Compounding Kit
3. CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line
4. CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding
5. Myoderm Expands International Capabilities
6. FDA Expands Use of Endovascular Graft to Treat Aortic Tears
7. Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities
8. FDA Expands Use of Prevnar 13 Vaccine for People Ages 50 and Older
9. Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
10. FDA Expands Use of HIV Drug Isentress to Children and Adolescents
11. Radient Pharmaceuticals Corporation Expands Distribution of Onko-Sure® in Asia; Receives Payment on First Order of 60 Kits
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):